Shared decision-making and patient decision aids in dermatology by Tan, Jerry et al.
Running head: SHARED DECISION-MAKING AND PATIENT DECISION AIDS IN DERMATOLOGY 
Shared decision-making and patient decision aids in dermatology  
 
Authors: Jerry Tan MD1, Eleni Linos MD DrPH2*, Myra A Sendelweck ME3*, Esther J 
van Zuuren MD4, Steven Ersser RN, PhD5 Robert P Dellavalle MD PhD MSPH6, Hywel 
Williams DSc FRCP7  
 
Affiliations: 
1 Western University, Ontario, Canada  
2 Department of Dermatology, University of California, San Francisco School of Medicine, 
California, USA 
3 University of Colorado, USA 
4 Department of Dermatology, Leiden University Medical Centre, Leiden, Netherlands 
5  School of Healthcare, University of Leeds, Leeds, UK 
6 Denver Veterans Affairs Medical Center, Colorado, USA 
7 Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK 
 
 
Corresponding author:  Jerry Tan MD FRCPC  jerrytan@bellnet.ca 
 
Conflict declarations: 
Jerry Tan holds the copyright for “What can you do to manage your psoriasis? A decision aid for 
plaque psoriasis patients.” 
Word count: 1179 
What this adds: 
• Shared decision making combines individual patient interests and values, and 
clinical best evidence under the guiding principle of patient autonomy. 
• Patient decision aids support shared decision making and facilitate decisions that 
have multiple options with varying outcomes for which patients may attribute 
different values. 
• Patient decision aids may provide accurate information on disease and treatment, 
establish the need for a decision, encourage deliberation of choices, clarify 
patient values and elicit preferences. 
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Patients are experts in their illness - they directly experience symptoms and 
psychosocial impact within the context of their personal circumstances. Health care 
providers are experts in management of disease with access to medical information and 
evidence. Shared decision making (SDM) reflects the importance of these two 
complementary experts with a convergence of patient interests and values combined 
with clinical expertise and best evidence around the central ethic of patient autonomy.1 
Medical innovation develops along a pathway of identifying clinical need, 
biomedical research and discovery, critical appraisal and synthesis, development of 
clinical practice guidelines (CPGs), and implementation into practice.2 While CPGs 
arose from the evidence-based medicine (EBM) movement and integrate best evidence, 
they are developed for care providers, not to assist patients with decision making. 
Closing this loop of innovation to a patient requires exploration of an individual’s  values 
and preferences. Several studies have found that a substantial percentage of patients 
would like to play a more active role in their healthcare decisions.3 Patient decision aids 
(pDAs) are tools to engage patients in this decision making. They are particularly suited 
for complex decisions that have multiple options with varying outcomes for which 
patients may attribute different values. Furthermore, in clinical situations in which 
outcome information is limited or uncertain, the best choice depends on the importance 
the patient places on each of the benefits, harms, and scientific uncertainties.4 In 
dermatology, the quality of medical evidence has improved substantially, but little has 
been done to incorporate SDM. Herein, we discuss SDM in dermatology, the 
effectiveness of pDAs, and their potential role in dermatology. 
 Dermatology is a specialty particularly suited to SDM as the severity of most 
dermatologic diseases is defined by patients’ experience of symptoms and adverse 
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psychosocial impact. Patients vary greatly in how they respond to dermatologic diseases 
as clinical determinants of severity often do not predict psychosocial impact. For 
example, some with severe acne may be unperturbed while others with few lesions may 
be highly distraught. Treatment decisions in dermatology are therefore particularly 
guided by personal characteristics, circumstances and preferences; beyond objective 
disease severity. Such decisions are especially important to share with patients who 
have a responsibility to self- manage chronic illness.  Accordingly, the majority of 
treatment decisions in dermatology should be preference-sensitive. Thus, what patients 
feel is important (values) should be a major determinant of the decision process. This is 
a patient-specific dimension that cannot be adequately answered by physicians 
responding to the question: what would you do, doctor? These factors may include 
convenience of treatment, product acceptability, cost, risk or side effects, onset of effect, 
overall efficacy, mode of administration, and potential for remission. In limited research 
of decisional roles in dermatology, the vast majority of dermatology patients wish to be 
actively involved in treatment decisions – 71% for psoriasis and 80% for melanoma.5,6  
Furthermore, most dermatological conditions have several treatment options with no 
singular gold standard, and sparse supportive evidence for alternative options. 
Examples include treatment of hidradenitis suppurativa, prurigo nodularis or chronic 
pruritus. A framework for shared decision-making in dermatology is shown in Figure 1.7 
This provides dermatologists an opportunity to work with patients in designing pDAs that 
inform about multiple treatment choices and to effectively communicate uncertainty 
about available evidence, while also eliciting patient values and preferences. An 
example of a decision aid in psoriasis can be accessed at <http://www.wcri.ca/wp-
content/uploads/2016/03/DECISION_AID-psx-v-Oct2012.pdf>.8 
SHARED DECISION-MAKING AND PATIENT DECISION AIDS IN DERMATOLOGY 
4 
 
Beyond provision of information on disease and treatment, pDAs can be designed 
to establish the need for a decision, encourage deliberation of choices, clarify patient 
values and elicit preferences. While pDAs were initially developed as simple decision 
boards diagramming risks and benefits for use during a medical encounter; they are now 
available in multiple other formats including interactive videodiscs, online formats, 
audiotapes, audio guided workbooks, and pamphlets for use before and after 
encounters to encourage self-reflection and deliberation.  
The preparation of these tools requires significant effort and rigorous 
methodology to ensure they are both user friendly, and scientifically accurate. The 
collection of decision aids is growing and promoted within some health systems 
(http://sdm.rightcare.nhs.uk/pda/; https://decisionaid.ohri.ca/AZinvent.php). Compared to 
standard care, pDAs have been shown to enhance knowledge about management 
options, reduce decisional conflict, encourage more active patient participation in 
decision making, and improve risk perceptions.9 For example, use of decision tools has 
been linked to choice of more conservative options rather than more invasive options.9 
Use of the psoriasis pDA showed that patients tended to self-select treatment 
appropriate to their level of psoriasis severity.10  Perhaps most importantly, decision 
tools are shown to improve ‘decision quality’ or ‘the match between the chosen option 
and the values that matter most to the patient’.
11,12 
 
Despite these benefits, there is a paucity of pDAs in dermatology. Presently, 
those that do exist address psoriasis7, basal cell cancer (BCC)13, acne14, and oral 
isotretinoin15 and were developed heterogeneously according to international standards 
or without clearly established methodological criteria. A key issue for the application of 
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pDAs is practicality. Little is known about the degree of detail required to provide a 
beneficial effect on decision-making. In general, simpler pDAs may be more practical for 
use in a clinical setting. However, brevity may impose restrictions on provision of 
adequate information on the condition, the range of management options, and detail 
about specific benefits and risks. Nevertheless, pDAs may be underutilized in busy 
clinical practices.16 Greater time invested in initial consultations to optimizing treatment 
decisions best suited to patients’ preferences may enhance adherence and reduce time 
required in follow up consultations. 
The Walter framework for individual decision-making at the end of life which was 
originally developed for screening decisions in older adults17, but has been adapted for 
care of skin cancer, anchors decisions through quantitative estimates of life expectancy 
and then incorporate risks and benefits of screening, can be adapted for management 
choices in BCC (Fig. 2). A pictorial representation of risks and benefits for oral 
antipsoriatic therapy is shown in Fig. 37. The final step involves incorporating the 
patient’s own values and preferences in making a fully informed and individualized 
decision. Practical pDAs that can facilitate these difficult decisions in a way that is 
feasible within the expertise and time constraints of a busy clinical dermatologist are 
urgently needed. 
CONCLUSION 
Informed shared decision-making supports patient autonomy and patient 
centered care. This process can be facilitated by development of pDAs derived from 
high-quality evidence-based systematic reviews transformed into decisional tools by 
clinical experts, patients and educators. They should be developed with a specific view 
to enhancing patient comprehension, maximizing relevance, and to being validated for 
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such outcomes. Additionally, they should be designed to enhance, rather than interfere, 
with patient-doctor communication within busy clinical settings. To enhance accessibility 
and use, they should be readily available in the public domain. Given the variable 
psychosocial impact of skin disease on individuals and relative uncertainty regarding 
best treatments and their adherence in many dermatologic conditions, informed shared 
decision making should constitute a central component of dermatologic care. The 
paucity of pDAs to support this process in dermatology reflects an unmet need. We 
encourage researchers, clinicians, patients and funding agencies to develop, 
disseminate and use pDAs to facilitate SDM in dermatology.    
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